Pesquisar
Abcellera Biologics Inc
ABCLAdicionar à lista de desejos
7.600USD
-0.250-3.18%
Fechamento 07/01, 16:00（ET）Cotações atrasadas em 15 min
2.31BValor de mercado
PerdaP/L TTM
Mais detalhes de Abcellera Biologics Inc Empresa
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Informações de Abcellera Biologics Inc
Código da empresaABCL
Nome da EmpresaAbcellera Biologics Inc
Data de listagemDec 11, 2020
CEOHansen (Carl L.G)
Número de funcionários596
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 11
Endereço150 W 4Th Avenue
CidadeVANCOUVER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalV5Y 1G6
Telefone16045599005
Sitehttps://www.abcellera.com/
Código da empresaABCL
Data de listagemDec 11, 2020
CEOHansen (Carl L.G)
Executivos da empresa Abcellera Biologics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
576.56K
+43.36%
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Stephen Quake
Mr. Stephen Quake
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
576.56K
+43.36%
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Abcellera Biologics Inc?
Os cinco principais acionistas de Abcellera Biologics Inc são: Dr. Veronique Lecault, Ph.D.
Quantas instituições possuem ações da Abcellera Biologics Inc (ABCL)?
Em 2026Q1, 323 instituições possuíam ações da Abcellera Biologics Inc, com valor de mercado aproximado de 131.69M, representando 43.14% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -19217264.00.
Qual é a maior fonte de receita da Abcellera Biologics Inc?
Em 2026Q1, o segmento de negócios Licensing revenue gerou a maior receita para Abcellera Biologics Inc, totalizando 46.92M e representando 62.45% da receita total.